Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study

被引:35
作者
Stefanelli, Paola [1 ]
Bella, Antonino [1 ]
Fedele, Giorgio [1 ]
Pancheri, Serena [2 ]
Leone, Pasqualina [1 ]
Vacca, Paola [1 ]
Neri, Arianna [1 ]
Carannante, Anna [1 ]
Fazio, Cecilia [1 ]
Benedetti, Eleonora [1 ]
Fiore, Stefano [1 ]
Fabiani, Concetta [1 ]
Simmaco, Maurizio [3 ]
Santino, Iolanda [3 ]
Zuccali, Maria Grazia [2 ]
Bizzarri, Giancarlo [2 ]
Magnoni, Rosa [2 ]
Benetollo, Pier Paolo [2 ]
Merler, Stefano [4 ]
Brusaferro, Silvio [5 ]
Rezza, Giovanni [6 ]
Ferro, Antonio [2 ]
机构
[1] Ist Super Sanita, Dept Infect Dis, Rome, Italy
[2] APSS Azienda Prov & Serv Sanit, Trento, Italy
[3] St Andrea Univ Hosp, Hosp Direct & Clin Dept, Rome, Italy
[4] Bruno Kessler Fdn, Ctr Informat Technol, Trento, Italy
[5] Ist Super Sanita, Rome, Italy
[6] Minist Hlth, Hlth Prevent Directorate, Rome, Italy
关键词
IgG; Infection fatality rate; Population-based study; SARS-CoV-2; Seroprevalence; SEROPREVALENCE;
D O I
10.1016/j.cmi.2020.11.013
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: A seroprevalence study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was conducted in a high-incidence area located in northeastern Italy. Methods: All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases, were invited to participate in the study. Among 6098 participants, 6075 sera and a standardized questionnaire administered face-to-face were collected between 5 May and 15 May 2020 and examined. Symptomatic individuals and their family contacts were tested by RT-PCR. Anti-SARS-CoV-2 antibodies were detected using an Abbott SARS-CoV-2 IgG assay, which was performed on the Abbott Architect i2000SR automated analyser. Seroprevalence was calculated as the proportion of positive results among the total number tested. A multivariable logistic regression model was performed to assess the relationship between seropositive versus seronegative individuals for a set of explanatory variables. Results: A total of 1402 participants were positive for IgG antibodies against SARS-CoV-2, with a prevalence of 23.1% (1402/6075). The highest prevalence was found in the age class 40-49 years. Overall, 34.4% (2096/6098) of the participants reported at least one symptom. The ratio between reported cases identified by molecular test and those with seropositive results was 1:3, with a maximum ratio of about 1:7 in the age group <20 years and a minimum around 1:1 in those >70 years old. The infection fatality rate was 2.5% (35/1402). Among the symptoms, anosmia and ageusia were strongly associated with seropositivity. Conclusions: The estimated seroprevalence of 23% was three-fold higher than the number of cases reported in the COVID-19 Integrated Surveillance data in the study area. This may be explained in part by a relatively high number of individuals presenting mild or no illness, especially those of younger age, and people who did not seek medical care or testing, but who may contribute to virus transmission in the community. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
引用
收藏
页码:633.e1 / 633.e7
页数:7
相关论文
共 50 条
  • [1] Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study)
    Jogi, Piia
    Soeorg, Hiie
    Ingerainen, Diana
    Soots, Mari
    Lattekivi, Freddy
    Naaber, Paul
    Toompere, Karolin
    Peterson, Part
    Haljasmagi, Liis
    Zusinaite, Eva
    Vaas, Hannes
    Pauskar, Merit
    Shablinskaja, Arina
    Kaarna, Katrin
    Paluste, Heli
    Kisand, Kai
    Oona, Marje
    Janno, Riina
    Lutsar, Irja
    VACCINE, 2021, 39 (38) : 5376 - 5384
  • [2] Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city
    Prakash, Om
    Solanki, Bhavin
    Sheth, Jay
    Oza, Divyang
    Kadam, Mina
    Vyas, Sheetal
    Shukla, Aparajita
    Pethani, Jayshri
    Tiwari, Hemant
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2021, 10 (06) : 2363 - 2368
  • [3] Prevalence of SARS-CoV-2 Antibodies in Kosovo-Wide Population-Based Seroepidemiological Study
    Ramadani, Naser
    Hoxha-Gashi, Sanije
    Gexha-Bunjaku, Dafina
    Kalaveshi, Arijana
    Jakupi, Xhevat
    Humolli, Isme
    Vaughan, Aisling
    Pebody, Richard
    Kacaniku-Gunga, Pranvera
    Jashari, Violeta
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2024, 18 (09)
  • [4] Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure
    Demonbreun, Alexis R.
    McDade, Thomas W.
    Pesce, Lorenzo
    Vaught, Lauren A.
    Reiser, Nina L.
    Bogdanovic, Elena
    Velez, Matthew P.
    Hsieh, Ryan R.
    Simons, Lacy M.
    Saber, Rana
    Ryan, Daniel T.
    Ison, Michael G.
    Hultquist, Judd F.
    Wilkins, John T.
    D'Aquila, Richard T.
    Mustanski, Brian
    McNally, Elizabeth M.
    JCI INSIGHT, 2021, 6 (09)
  • [5] Characterization of IgG Antibody Response against SARS-CoV-2 (COVID-19) in the Cypriot Population
    Krashias, George
    Deeba, Elie
    Constantinou, Astero
    Hadjiagapiou, Maria
    Koptides, Dana
    Richter, Jan
    Tryfonos, Christina
    Bashiardes, Stavros
    Lambrianides, Anastasia
    Loizidou, Maria A.
    Hadjisavvas, Andreas
    Panayiotidis, Mihalis I.
    Christodoulou, Christina
    MICROORGANISMS, 2022, 10 (01)
  • [6] SARS-CoV-2 infection incidence during the first and second COVID-19 waves in Italy
    Vinceti, Marco
    Filippini, Tommaso
    Rothman, Kenneth J.
    Di Federico, Silvia
    Orsini, Nicola
    ENVIRONMENTAL RESEARCH, 2021, 197
  • [7] Serosurveillance among COVID-19 Cases in Ahmedabad Using SARS-COV2 IgG Antibodies
    Prakash, Om
    Solanki, Bhavin
    Sheth, Jay
    Maitrak, Daxa
    Kadam, Mina
    Vyas, Sheetal
    Shukla, Aparajita
    Tiwari, Hemant
    INDIAN JOURNAL OF COMMUNITY HEALTH, 2021, 33 (02) : 351 - 356
  • [8] National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic
    Palmateer, N. E.
    Dickson, E.
    Furrie, E.
    Godber, I
    Goldberg, D. J.
    Gousias, P.
    Jarvis, L.
    Mathie, L.
    Mavin, S.
    McMenamin, J.
    McNeilly, T. N.
    Murcia, P.
    Murray, J.
    Reid, G.
    Robertson, C.
    Templeton, K.
    von Wissmann, B.
    Wallace, L. A.
    Waugh, C.
    McAuley, A.
    PUBLIC HEALTH, 2021, 198 : 102 - 105
  • [9] High prevalence of SARS-CoV-2 antibodies in pets from COVID-19+ households
    Fritz, Matthieu
    Rosolen, Beatrice
    Krafft, Emilie
    Becquart, Pierre
    Elguero, Eric
    Vratskikh, Oxana
    Denolly, Solene
    Boson, Bertrand
    Vanhomwegen, Jessica
    Gouilh, Meriadeg Ar
    Kodjo, Angeli
    Chirouze, Catherine
    Rosolen, Serge G.
    Legros, Vincent
    Leroy, Eric M.
    ONE HEALTH, 2020, 11
  • [10] The Seroprevalence of SARS-CoV-2 in Children During Early COVID-19 Pandemic in Korea: A Nationwide, Population-Based Study
    Lee, Jin
    Choe, Young June
    Minn, Dohsik
    Kim, Jong-Hyun
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, 37 (44)